The Science Behind Why Ketamine Works When Antidepressants Don't
A recent review in Psychiatric Times (April 2026) lays out why glutamate-targeting treatments are becoming the clinical standard for treatment-resistant depression (TRD) — and the findings have direct relevance for anyone using or considering ketamine troches as part of their mental health care.
For decades, depression treatment was almost entirely built around monoamine neurotransmitters — serotonin, dopamine, and norepinephrine. SSRIs, SNRIs, and MAOIs all work by modulating these pathways. But for roughly one-third of people with major depressive disorder, those pathways simply don't deliver adequate relief. That's the population defined as having treatment-resistant depression, and it's a large one.
The review highlights how glutamate — the brain's primary excitatory neurotransmitter — offers a fundamentally different mechanism. Rather than slowly adjusting monoamine availability over weeks, glutamatergic agents like ketamine trigger rapid synaptogenesis: the formation of new synaptic connections. This is the neurobiological basis for ketamine's most clinically distinctive feature — speed. Relief can begin within hours rather than weeks.
Two agents receive primary focus in the review: esketamine (marketed as Spravato, administered as a nasal spray in clinical settings) and dextromethorphan-bupropion (Auvelity, an oral combination tablet). Both act on the NMDA receptor, the same glutamate receptor that ketamine targets. Their emergence as FDA-approved TRD options has validated the glutamatergic approach and opened a wider clinical conversation about which delivery format best fits a patient's life.
Where Ketamine Troches Fit in This Evolving Landscape
The review's clinical framing is important context for troche patients. Compounded ketamine troches occupy a specific and practical niche in the glutamatergic treatment space — one that the FDA-approved options don't fully cover.
Esketamine nasal spray requires in-office administration with a mandatory two-hour post-dose monitoring window. It's effective, but the logistics are demanding: frequent clinic visits, scheduling constraints, and cost barriers that insurance coverage doesn't always resolve. IV ketamine infusions go even further in that direction — highly controlled, clinically intensive, and priced out of reach for many patients without significant out-of-pocket resources.
Dextromethorphan-bupropion offers genuine at-home convenience as a daily oral tablet, but its mechanism, dosing profile, and onset characteristics differ meaningfully from ketamine. It's not a direct substitute, and clinicians treat it as a distinct option rather than an equivalent one.
Troches — sublingual or buccal dissolvable lozenges made by compounding pharmacies — sit between these poles. They're administered at home, which removes the clinic-visit burden. They use racemic ketamine (both R- and S-enantiomers), not the isolated esketamine in Spravato, giving prescribers more flexibility in dosing. Because they dissolve under the tongue or against the cheek, absorption begins through the oral mucosa before the remainder passes through the GI tract — a dual-absorption pathway that compounding pharmacists can calibrate for individual patient needs.
Critically, troches maintain the core glutamatergic mechanism that the Psychiatric Times review identifies as the reason these treatments work when monoamine-based therapies don't. The synaptogenic effect — that rapid rewiring of depressive neural circuits — is not unique to IV or nasal delivery. It's a property of the molecule itself, expressed across administration routes at appropriate doses.
That said, bioavailability does vary. IV infusions deliver ketamine with near-complete systemic availability. Troches, by comparison, have more variable absorption depending on saliva production, how long the troche is held in the mouth, and individual patient metabolism. This is why titration and close prescriber follow-up remain essential components of a responsible troche protocol — it's not a set-it-and-forget-it format.
Key Takeaway for Troche Patients
The growing clinical recognition of glutamatergic treatments validates the mechanism behind your troche prescription — but format still matters. Troches offer real-world flexibility that IV and nasal options can't match, while the synaptogenic benefits remain intact. Work closely with your prescriber to ensure your dose and dosing schedule are calibrated to your absorption profile, not just copied from an infusion protocol. The science supports the approach; the details of your individual regimen determine the outcome.
Practical Implications for 2026 Treatment Decisions
For patients navigating TRD in 2026, the expanding body of glutamatergic research carries several practical implications worth understanding before your next prescriber conversation.
The mechanism is now mainstream medicine. Five years ago, ketamine for depression was still viewed skeptically in many clinical corners. The continued publication of peer-reviewed reviews in outlets like Psychiatric Times — alongside two FDA-approved glutamatergic agents — signals that this is no longer fringe treatment. That matters for insurance conversations, for finding qualified prescribers, and for patients who have faced stigma around ketamine-based care.
Delivery format should match your life, not just the clinical default. The review doesn't declare one format superior — and that's the honest answer. Infusions may be appropriate for acute crisis intervention or initial treatment. Esketamine nasal spray suits patients who prefer clinic-administered sessions with structured monitoring. Troches are well-suited for maintenance phases, for patients in areas without infusion centers, and for those who need a sustainable long-term protocol rather than episodic intensive treatment.
Compounding quality remains non-negotiable. As glutamatergic treatments gain mainstream acceptance, demand for compounded ketamine is rising. Not all compounding pharmacies operate to the same standard. Patients using troches should confirm their pharmacy holds current PCAB accreditation or equivalent state-level oversight, and that their prescriber is sourcing from a pharmacy with documented quality controls. The clinical science only delivers its promise when the compounded product is consistent and accurately dosed.
Synaptogenesis takes time to consolidate. The rapid-onset effect of ketamine is well-documented, but the review's emphasis on synaptogenesis as the durable mechanism is a reminder that the goal isn't just fast relief — it's structural neural change. That process benefits from consistency. Erratic dosing schedules, unsupervised dose escalation, or stopping troches abruptly when symptoms improve can interrupt the consolidation of those new synaptic pathways. Treatment planning should account for a full protocol arc, not just symptom-by-symptom response.
The glutamatergic pathway is no longer an experimental detour from mainstream depression care. It is mainstream depression care for TRD. Ketamine troches are a clinically and logistically viable way to access that pathway — and understanding the underlying science makes patients better advocates for their own treatment plans.
Share